Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:GHRS NASDAQ:MIRM NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.86+0.3%$37.97$10.95▼$40.26$5.93B1.111.02 million shs1.46 million shsGHRSGH Research$24.83+3.5%$18.74$10.96▼$25.24$1.65B1.31222,786 shs285,451 shsMIRMMirum Pharmaceuticals$96.33-5.1%$97.01$43.50▼$114.99$6.19B0.51.30 million shs599,062 shsTGTXTG Therapeutics$37.41-1.4%$36.35$25.28▼$44.65$5.81B1.682.06 million shs1.64 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+0.25%+0.28%+0.73%+52.14%+203.35%GHRSGH Research+3.50%+12.25%+19.89%+62.29%+107.26%MIRMMirum Pharmaceuticals-5.09%-2.32%-0.21%+9.72%+117.25%TGTXTG Therapeutics-1.40%-3.76%+10.57%+29.54%+5.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.86+0.3%$37.97$10.95▼$40.26$5.93B1.111.02 million shs1.46 million shsGHRSGH Research$24.83+3.5%$18.74$10.96▼$25.24$1.65B1.31222,786 shs285,451 shsMIRMMirum Pharmaceuticals$96.33-5.1%$97.01$43.50▼$114.99$6.19B0.51.30 million shs599,062 shsTGTXTG Therapeutics$37.41-1.4%$36.35$25.28▼$44.65$5.81B1.682.06 million shs1.64 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+0.25%+0.28%+0.73%+52.14%+203.35%GHRSGH Research+3.50%+12.25%+19.89%+62.29%+107.26%MIRMMirum Pharmaceuticals-5.09%-2.32%-0.21%+9.72%+117.25%TGTXTG Therapeutics-1.40%-3.76%+10.57%+29.54%+5.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 2.21Hold$41.333.70% UpsideGHRSGH Research 2.73Moderate Buy$40.3862.61% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$137.0842.30% UpsideTGTXTG Therapeutics 2.57Moderate Buy$52.5040.34% UpsideCurrent Analyst Ratings BreakdownLatest GHRS, MIRM, TGTX, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.005/22/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/19/2026MIRMMirum Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.005/19/2026GHRSGH Research HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/19/2026MIRMMirum Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.005/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.005/7/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$128.00 ➝ $142.00(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$15M396.55N/AN/A$3.92 per share10.17GHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/AMIRMMirum Pharmaceuticals$521.31M11.27$0.05 per share1,991.01$6.12 per share15.74TGTXTG Therapeutics$700.35M8.18$2.76 per share13.54$4.08 per share9.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)GHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A602.06N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8613.0813.46N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest GHRS, MIRM, TGTX, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A3/6/2026Q4 2025GHRSGH Research-$0.29-$0.23+$0.06-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.239.539.53GHRSGH ResearchN/A34.1334.13MIRMMirum Pharmaceuticals1.282.091.99TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%GHRSGH Research56.90%MIRMMirum PharmaceuticalsN/ATGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals4.09%GHRSGH ResearchN/AMIRMMirum Pharmaceuticals8.32%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200149.23 million143.13 millionOptionableGHRSGH Research1068.61 millionN/AOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableGHRS, MIRM, TGTX, and CNTA HeadlinesRecent News About These CompaniesTG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ...June 1 at 8:48 AM | finance.yahoo.comTG Therapeutics Reports Significant Efficacy of BRIUMVI in Treating Treatment-Naïve Patients with Relapsing Multiple SclerosisJune 1 at 8:10 AM | quiverquant.comQTG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ImmunologyJune 1 at 7:30 AM | globenewswire.comAnalysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Apogee Therapeutics (APGE) and Boston Scientific (BSX)May 30 at 12:54 AM | theglobeandmail.comTG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 OutlookMay 28, 2026 | seekingalpha.comTGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS StudyMay 28, 2026 | zacks.comTG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comTG Therapeutics, Inc.: TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE TrialMay 27, 2026 | finanznachrichten.deTG Therapeutics Inc Stock GuidanceMay 27, 2026 | benzinga.comTG Therapeutics posts late-stage trial win for Briumvi single infusion regimenMay 27, 2026 | seekingalpha.comTG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE TrialMay 27, 2026 | globenewswire.comTG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple ...May 26, 2026 | caledonianrecord.comCTG Therapeutics to Present New Data on BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual MeetingMay 26, 2026 | quiverquant.comQTG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual MeetingMay 26, 2026 | globenewswire.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 25, 2026 | americanbankingnews.comMultiple sclerosis-focused biotech quadruples its profit, raises sales forecastMay 22, 2026 | msn.comTGTX Stock Rises 29% in 3 Months: Here's What You Should KnowMay 20, 2026 | zacks.comTG Therapeutics Stock Story Gains Interest In Nasdaq IndexMay 13, 2026 | kalkinemedia.comKTG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They AppearMay 13, 2026 | finance.yahoo.comHistoric Signal Says This Biotech OutperformsMay 11, 2026 | schaeffersresearch.comQ2 EPS Estimates for TG Therapeutics Increased by AnalystMay 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026GHRS, MIRM, TGTX, and CNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$39.86 +0.10 (+0.25%) Closing price 06/1/2026 04:00 PM EasternExtended Trading$39.86 0.00 (0.00%) As of 06/1/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.GH Research NASDAQ:GHRS$24.83 +0.84 (+3.50%) Closing price 06/1/2026 04:00 PM EasternExtended Trading$25.17 +0.34 (+1.39%) As of 06/1/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Mirum Pharmaceuticals NASDAQ:MIRM$96.33 -5.17 (-5.09%) Closing price 06/1/2026 04:00 PM EasternExtended Trading$97.08 +0.75 (+0.77%) As of 06/1/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.TG Therapeutics NASDAQ:TGTX$37.41 -0.53 (-1.40%) Closing price 06/1/2026 04:00 PM EasternExtended Trading$37.47 +0.06 (+0.15%) As of 06/1/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
